Navigation Links
NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinson's Disease
Date:11/9/2011

>"One of our priorities at MJFF is to drive research that could improve the quality of life for people living with PD today," said Brian Fiske, PhD, director of research programs at MJFF.  "NeuroDerm is working to develop a therapy that might do just that.  By providing a more even and continuous supply of levodopa to the brain, ND0611 has the potential to limit the motor fluctuations that many patients experience during periods when their medication wears off."

"ND0611's remarkable success in its first phase I/II trial significantly raises the probability of it becoming a new treatment option for PD patients. ND0611 is unique: it is the first drug developed to administer carbidopa systemically; it acts directly on levodopa metabolism not only in the gastrointestinal tract; and it probably employs a different mode of action than orally administered carbidopa," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "ND0611 has now been shown to improve levodopa's bioavailability in patients with any type of oral levodopa drug used even improving the bioavailability of what is considered to be the best current levodopa oral therapy. One can now realistically hope that ND0611 may eventually establish a higher standard of care for PD patients undergoing oral LD therapy".

About the phase I/II Safety and Pharmacokinetic Study

This placebo controlled, randomized, double-blind, six-way crossover trial enrolled 24 patients with advanced Parkinson's disease. All patients were administered the three most commonly-used levodopa therapies (immediate-release Sinemet®, Sinemet®-CR, and Stalevo®) in 100mg dosage four times per day; in addition they received either ND0611 or placebo.

In addition to evaluating safety and tolerability, the study's primary endpoint was improvement in levodopa half life in all treatment arms; secondary endpoints included additional PK parameters. All PK parameters
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
3. China Sky One Medical Announces Third Quarter 2011 Results
4. China Information Technology, Inc. Announces Third Quarter 2011 Results
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
8. MedBox Announces Ticker Symbol Change
9. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
10. ECRI Institute Announces its Top 10 Health Technology Hazards for 2012
11. Echo Therapeutics Announces Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015   Cypher Genomics, Inc., ... data showing that, compared to a panel of ... highly equivalent interpretations of whether certain genetic abnormalities ... in a fraction of the time. Cypher,s Mantis ... comprehensive genetic analysis in non-invasive prenatal testing (NIPT) ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... HARBIN, China , ... Sheets: RHGP) ("Renhuang" or the "Company"), a,developer, manufacturer ... medicines ("TCM"), today announced,that the Company successfully exhibited ... Harbin International Economic,and Trade Fair ("Harbin Trade Fair") ...
... Mass. , July 1 Shire plc (LSE: ... today announced positive data from its long-term extension to its ... alfa), the company,s enzyme replacement therapy for patients with type ... Annual European Working Group on Gaucher Disease (EWGGD) in ...
Cached Medicine Technology:Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair 2Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair 3Renhuang Pharmaceuticals Exhibits Siberian Ginseng Products at the 21st China Harbin International Economic and Trade Fair 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 2Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 3Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 5Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 6
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
(Date:3/27/2015)... Red Deer, Alberta (PRWEB) March 27, 2015 ... had, until then, prevented her from working, Monica K. arrived ... day in the mending department quiet, defensive and scared. The ... Employment Placement & Support Services (EPSS) to offer jobs ... it does take patience and a willingness to begin with ...
(Date:3/27/2015)... York, NY (PRWEB) March 27, 2015 ... seeing more plastic surgery patients travel to the Dominican ... Medina. The plastic surgery clinic is turning the medical ... international cosmetic surgery patients — with trustworthy services becoming ... factor when selecting a plastic surgeon. Patients are not ...
(Date:3/27/2015)... San Jose, CA (PRWEB) March 27, 2015 ... last week’s 2015 GPU technology conference (GTC) , the ... to fight cancer and push the human lifespan well beyond ... Baltimore MD informatics company , is one of 12 ... , While other startups in the GTC Emerging ...
(Date:3/27/2015)... March 27, 2015 Endure Yoga is ... functional fitness athletes. This new program matches yoga poses ... for post-workout cool down. This program utilizes yoga to ... and mental focus. , Karen Lefurgy, competitive athlete ... yoga long before I started Crossfit® training, but quickly, ...
Breaking Medicine News(10 mins):Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:Endure Yoga Introduces WOD Recovery Yoga 2
... The Center for ... with the flu (influenza). On average, the influenza virus leads to 20,000 to 40,000 American ... deaths by offering free flu shots . , ... Plano, TX (Vocus) September 12, 2009 -- Starting Monday, September 14th, the Plano location ...
... Hernandez, Ph.D., M.P.H.an assistant professor at the University of ... that body mass in younger and older adulthood, and ... man,s risk for prostate cancer. This risk varies among ... study published in Cancer Epidemiology, Biomarkers & Prevention ...
... , TAMPA, Fla. and SAN FRANCISCO, Sept. ... agreement to roll out Demandforce D3, a web-based patient communications ... in Florida and Georgia. Coast Dental, the leading dental provider ... pilot. , , Coast Dental integrated the ...
... NEW YORK, Sept. 11 Duane Reade Holdings Inc., ... as the Local Presenting Sponsor of the 2009 Komen New York ... foundation, The Duane Reade Charitable Foundation, have raised $330,000 to increase ... find a cure. This marks the third year that Duane Reade ...
... , LIONVILLE, Pa., Sept. 11 ... that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, ... 7th Annual Best Ideas Conference 2009, being held September 16-17, 2009 ... the UBS Global Life Sciences Conference, being held September 21-23, 2009 ...
... ROCHESTER, Minn., Sept. 11 Mayo Clinic researchers ... may help them diagnose cardiac infections without an invasive exam. ... on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. , ... ) , , Endocarditis -- an infection ...
Cached Medicine News:Health News:H1N1 frenzy may allow regular flu to be more deadly than ever 2Health News:University of Hawaii at Manoa CRCH scientists report adulthood body size associated with cancer risk 2Health News:Coast Dental Deploys Demandforce D3 Communications Platform 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 2Health News:New Yorkers Help Duane Reade Increase Support of the 19th Annual Komen New York City Race For The Cure(R) 3Health News:West to Present at Two Upcoming Investor Conferences 2Health News:Artificial Intelligence Helps Diagnose Cardiac Infections 2Health News:Artificial Intelligence Helps Diagnose Cardiac Infections 3
... the examination of the anatomical conditions in the ... expanse and form of the iridocorneal angle can ... beam. The slit lamp 900, with its swivelling ... an assessment of the expanse of the entire ...
An antegrade femoral nail....
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... stimulation is a non-invasive and painless method ... system. Cadwell Laboratories manufactures two magnetic stimulation ... Magnetic Stimulator (HSMS). The Hight ... stimulation rates up to 25 Hz at ...
Medicine Products: